• Read more about INSPIRE-CRT

Short Title: INSPIRE-CRT

The INSPIRE-LUNG-CRT trial is a prospective, pilot study investigating the efficacy of incentive spirometry on the incidence and severity of pneumonitis in lung cancer patients undergoing concurrent chemotherapy and radiation therapy with immunotherapy maintenance. Despite advancements in treatment modalities, pulmonary complications remain a significant challenge, often leading to diminished functional capacity and quality of life. This trial aims to establish incentive spirometry as a non-pharmacological intervention to reduce these complications, thereby improving clinical outcomes and patient well-being. Lung cancer treatments are frequently associated with pulmonary toxicities, such as radiation-induced pneumonitis and fibrosis, immunotherapy induced pneumonitis, significantly impacting patient outcomes. Incentive spirometry, a device that encourages deep breathing and lung expansion, has shown promise in postoperative settings but is underutilized in oncology.

Study Number:

INSPIRE-CRT

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT06688422

Disease:

• Lung Cancer,
• Non-Small-Cell Lung Cancer (NSCLC)

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• Veli Bakalov, MD

Department:

• Hematology and Medical Oncology

• Read more about NRG CC011

Short Title: CC011

The goal of this trial is to determine the efficacy of advanced cognitive training for cancer survivors suffering from cancer- and cancer-treatment-related cognitive dysfunction. For millions of cancer survivors, cognitive dysfunction is a prevalent, severe, and persistent problem that has long been associated with poor work-related and health-related outcomes. Evidence suggests that a significant subset of breast cancer survivors (BCS) incur cognitive changes that may persist for years after treatment. Unfortunately, the scientific basis for managing these cognitive changes is extremely limited. Available evidence from pilot studies, including our work, suggests that advanced cognitive training, which is based on the principles of neuroplasticity (ability of brain neurons to re-organize and form new neural networks), may be a viable treatment option. However, previous trials to date have been limited by lack of attention-controlled designs, small samples of BCS, or limited outcome measures. Therefore, to overcome limitations of past studies and build on our pilot results, the purpose of this 2-group, double-blind, randomized controlled trial is to conduct a full-scale efficacy trial to compare advanced cognitive training to attention control in BCS.

NRG CC011 is Temporarily on Hold effective Friday, May 9, 2025, at 5 pm EDT until further notice.

Study Number:

CC011

Study Status:

Enrolling

Treatment Agent:

N/A

Resources and Links

National Clinical Trial Identified Number: NCT05896189

Disease:

• Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Danny Markabawi, MD

Department:

• Hematology and Medical Oncology

• Read more about BN012

Short Title: BN012

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.

Study Number:

BN012

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT05438212

Disease:

• Metastatic Malignant Neoplasm in the Brain,
• Brain Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Justin M. Mann, MD

Department:

• Radiation Therapy

• Read more about EMBER-4

Short Title: EMBER-4

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return.

Study Number:

EMBER-4

Study Status:

Enrolling

Treatment Agent:

Imlunestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane

Resources and Links

National Clinical Trial Identified Number: NCT05514054

Disease:

• Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Emily Walzer, MD

Department:

• Breast Cancer

• Read more about IOV-EAP-402

Short Title: IOV-EAP-402

The objective of this expanded access protocol is to provide access to Out of Specification (OOS) AMTAGVI treatment to patients. This program provides access to OOS AMTAGVI (lifileucel) that does not meet commercial release criteria but does meet Iovance clinical trial release criteria. Patients will be followed for safety and efficacy.

Study Number:

IOV-EAP-402

Study Status:

Enrolling

Treatment Agent:

AMTAGVI

Resources and Links

National Clinical Trial Identified Number: NCT05398640

Disease:

• Melanoma

Study Phase:

N/A

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Skin Cancer,
• Melanoma and Skin Cancer Center,
• Surgical Oncology

• Read more about Timothy D. Marks, DNP, MBA, RN, CEN, NEA-BC

Dr. Marks joined Cooper University Health Care in 2022. He is responsible for developing and maintaining key local, regional, and national academic as well as workforce partnerships with a focus on nursing and patient care services workforce career advancement and professional development opportunities.

• Read more about Tammy Huster, MBA, MAS, BSN, RN, CMSRN, NE-BC, FACHE

Ms. Huster joined Cooper University Health Care in 2020. She has operational oversight of all medical/surgical units.

Prior to joining Cooper, Ms. Huster served in various nursing and leadership roles at Virtua Health System in South Jersey for over 15 fifteen years. She also served in the United States Army/Reserves for 17 years in various clinical roles from medic to licensed practical nurse and finally as a registered nurse.

• Read more about Nowai Brapoh, PhD, RN, NPD-BC

Dr. Brapoh joined Cooper University Health Care in 2023. She provides strategic oversight for nursing quality, education, professional development, and wound care. 

• Read more about Marilyn Mapp, DNP, RN, NEA-BC

Dr. Mapp joined Cooper University Health Care in 2023. She provides operational oversight for the Women’s and Children’s Institute, including Obstetrics and Gynecology, Pediatrics, Child Life, Neonatal and Pediatric Critical Care, Cleft Palate Clinic, and the Safe Kids Outreach Program as well as Respiratory, Pulmonary Function Testing, and Interventional Pulmonary. 

• Read more about Karen Gruber, BSN, RN, CEN, NE-BC

Ms. Gruber joined Cooper in 1989 and has advanced from a staff nurse to her current position of Assistant Vice President, Nursing Operations. She provides operational oversight for Emergency Services, Urgent Care Centers, Inpatient Psychiatry, Cooper Transfer Center, Supplemental Staffing, and Logistics.